Reviews
Cell therapies for refractory rheumatoid arthritis
R. Liu1, P. Zhao2, W. Tan3, M. Zhang4
- Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. miaojia_zhang@163.com
CER10977
2018 Vol.36, N°5
PI 0911, PF 0919
Reviews
Free to view
(click on article PDF icon to read the article)
PMID: 29745893 [PubMed]
Received: 21/11/2017
Accepted : 05/02/2018
In Press: 08/05/2018
Published: 26/09/2018
Abstract
Rheumatoid arthritis (RA), an autoimmune disease, is characterised by a persistent synovitis in the joints and systemic inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and disease-modifying antirheumatic drugs (DMARDs) are widely used to treat RA patients. However, a portion of patients still have inadequate response to traditional medications. Recently, cell-based therapies have become the focus, attracting more attention due to their potential for remission induction. Several immune-regulatory cell types, such as haematopoietic stem cells, mesenchymal stem cells and regulatory T cells have been defined as novel targets. In this paper, we have summarised and reviewed current clinical trials using cell-based therapeutic approaches for the treatment of RA.
